CSPC Pharmaceutical Group Ltd. has announced that their Investigational New Drug $(IND.AU)$ application for SYS6040, an antibody-drug conjugate, has received clinical trial approval from the U.S. Food and Drug Administration (FDA). This approval allows CSPC to conduct clinical trials in the U.S. for the treatment of advanced solid tumors. Additionally, the product obtained approval from China's National Medical Products Administration in March 2025 to conduct similar trials in China. SYS6040 is a monoclonal antibody-drug conjugate designed to target specific tumor receptors, releasing toxins to kill cancer cells. Preclinical studies have shown promising anti-tumor effects across various cancers. CSPC has also submitted several patent applications for SYS6040 both in China and internationally.